Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02807805 · ClinicalTrials.gov registry record · Phase 2

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

A Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by Mamta Parikh.

Active
Registry status
Phase 2
Development phase
37
Enrollment target
1
Study location

NCT02807805 is a Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma that is active but no longer recruiting, run by Mamta Parikh. The registered enrollment target is 37 participants, below the 132-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02807805, a Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, is active but no longer recruiting, sponsored by Mamta Parikh.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by lowering the amount of androgen the body makes. Niclosamide is a drug that may block another signal that can cause prostate cancer cell growth. Prednisone is a drug that can help lessen inflammation. Giving abiraterone acetate, niclosamide, and prednisone may be a better treatment for patients with hormone-resistant prostate cancer.

Conditions Studied

Metastatic Prostate Carcinoma Recurrent Prostate Carcinoma Stage IV Prostate Cancer

Interventions

  • DRUG Prednisone
  • DRUG Abiraterone Acetate
  • DRUG Niclosamide

Study Locations (1)

California

  • University of California Davis Comprehensive Cancer Center - Sacramento

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2016-10
Est. Completion 2025-12
Phase Phase 2

Sponsor

Mamta Parikh

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02807805

The ClinicalTrials.gov registry entry for NCT02807805 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (72% lower). The listed sponsor is Mamta Parikh, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.

NCT02807805 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02807805 about?

NCT02807805 is a clinical study titled "Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer". This phase II trial studies the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by loweri...

What is the current status of trial NCT02807805?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2016-10. Estimated completion is 2025-12.

What conditions does trial NCT02807805 study?

This clinical trial studies the following conditions: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer.

What interventions are being tested in trial NCT02807805?

The interventions under investigation include: Prednisone (DRUG), Abiraterone Acetate (DRUG), Niclosamide (DRUG).

Who is sponsoring clinical trial NCT02807805?

This trial is sponsored by Mamta Parikh, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02807805 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Carcinoma

All registered trials for this condition

Recurrent Prostate Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.